1
|
Sangnier M, Bouguéon G, Berroneau A, Dubois V, Crauste-Manciet S. Removal of bacterial growth inhibition of anticancer drugs by using complexation materials. Pharmaceutical Technology in Hospital Pharmacy 2020. [DOI: 10.1515/pthp-2019-0018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
AbstractIn the context of batch production of cytotoxic drugs in hospital pharmacies with the need of sterility testing, the objective was to validate the use of Rapid Microbiological Method (RMM), and to develop adequate neutralization method in case of inhibition of bacterial growth. The potential microbiological growth inhibitory effect of three anticancer drugs (5 fluorouracil, irinotecan and oxaliplatin) selected for batch production was assessed on BacT/ALERT® system. Among cytotoxic drugs, only 5FU exhibited inhibitory effect on microbiological growth using rapid microbiological method. To counteract this effect our purpose was to use neutralizing agents complexing the drug i. e. activated carbon or ion exchange resins. The microbiological bactericidal concentration of 5FU was very low (1.10–4 mg/mL) indicating the absolute need to neutralize the whole drug before sterility test. The complexation was validated by High Performance Liquid Chromatography control of the residual 5FU concentration in solution after the use of neutralizing agents. Only activated carbon was able to fully capture 5FU when previously diluted at 5 mg/mL. Conversely, the resins, in the condition of the study, were not able to fully capture 5FU whatever the dilution. The microbiological growth on BacT/ALERT® system after active carbon treatment was successfully confirmed with Staphylococcus aureus. Based on this validation results a method was then developed to routinely be able to perform sterility test of the batches produced and was confirmed on five microbiological species (i. e. S. aureus, Pseudomonas aeruginosa, Bacillus subtilis, Candida albicans, Aspergillus brasiliensis). Our work gives a new insight for considering sterility testing by rapid microbiological method even for drugs exhibiting inhibitory effect on microbiological growth.
Collapse
Affiliation(s)
- Maïté Sangnier
- Pharmaceutical Technology Department, Bordeaux University Hospital, Avenue de Magellan, Pessac, France
| | - Guillaume Bouguéon
- Pharmaceutical Technology Department, Bordeaux University Hospital, Avenue de Magellan, Pessac, France
- ARNA Laboratory-ChemBioPharm U1212 INSERM – UMR5320, CNRS – University of Bordeaux, 146 rue Léo Saignat, Bordeaux, France
| | - Aude Berroneau
- Pharmaceutical Technology Department, Bordeaux University Hospital, Avenue de Magellan, Pessac, France
| | - Véronique Dubois
- Fundamental Microbiology and Pathogenicity Laboratory UMR-CNRS 5234 – University of Bordeaux, 146 rue Léo Saignat, Bordeaux, France
- Microbiology Department, Bordeaux University Hospital, Place Amélie Rabat Léon, Bordeaux Cedex, France
| | - Sylvie Crauste-Manciet
- Pharmaceutical Technology Department, Bordeaux University Hospital, Avenue de Magellan, Pessac, France
- ARNA Laboratory-ChemBioPharm U1212 INSERM – UMR5320, CNRS – University of Bordeaux, 146 rue Léo Saignat, Bordeaux, France
| |
Collapse
|
2
|
Dessane B, Smirani R, Bouguéon G, Kauss T, Ribot E, Devillard R, Barthélémy P, Naveau A, Crauste-Manciet S. Nucleotide lipid-based hydrogel as a new biomaterial ink for biofabrication. Sci Rep 2020; 10:2850. [PMID: 32071330 PMCID: PMC7029012 DOI: 10.1038/s41598-020-59632-w] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2019] [Accepted: 01/20/2020] [Indexed: 12/30/2022] Open
Abstract
One of the greatest challenges in the field of biofabrication remains the discovery of suitable bioinks that satisfy physicochemical and biological requirements. Despite recent advances in tissue engineering and biofabrication, progress has been limited to the development of technologies using polymer-based materials. Here, we show that a nucleotide lipid-based hydrogel resulting from the self-assembly of nucleotide lipids can be used as a bioink for soft tissue reconstruction using injection or extrusion-based systems. To the best of our knowledge, the use of a low molecular weight hydrogel as an alternative to polymeric bioinks is a novel concept in biofabrication and 3D bioprinting. Rheological studies revealed that nucleotide lipid-based hydrogels exhibit suitable mechanical properties for biofabrication and 3D bioprinting, including i) fast gelation kinetics in a cell culture medium and ii) shear moduli and thixotropy compatible with extruded oral cell survival (human gingival fibroblasts and stem cells from the apical papilla). This polymer-free soft material is a promising candidate for a new bioink design.
Collapse
Affiliation(s)
- Bérangère Dessane
- ARNA Laboratory, Inserm, U1212, CNRS 5320 (ChemBioPharm), University of Bordeaux, F-33000, Bordeaux, France
- Pharmaceutical Technology Department, University Hospital of Bordeaux, CHU de Bordeaux, Avenue de Magellan, 33604, Pessac, France
| | - Rawen Smirani
- Biotis, Inserm, U1026 University of Bordeaux 146 rue Léo-Saignat, Case 45 CEDEX 33076 F-, 33000, Bordeaux, France
- Department of Oral Medicine University Hospital of Bordeaux, CHU de Bordeaux, Place Amélie Rabat Léon, 33076, Bordeaux Cedex, France
| | - Guillaume Bouguéon
- ARNA Laboratory, Inserm, U1212, CNRS 5320 (ChemBioPharm), University of Bordeaux, F-33000, Bordeaux, France
- Pharmaceutical Technology Department, University Hospital of Bordeaux, CHU de Bordeaux, Avenue de Magellan, 33604, Pessac, France
| | - Tina Kauss
- ARNA Laboratory, Inserm, U1212, CNRS 5320 (ChemBioPharm), University of Bordeaux, F-33000, Bordeaux, France
| | - Emeline Ribot
- Center for Magnetic Resonance for Biological System UMR 5536, CNRS, University of Bordeaux 146 rue Léo Saignat, 33076, Bordeaux, France
| | - Raphaël Devillard
- Biotis, Inserm, U1026 University of Bordeaux 146 rue Léo-Saignat, Case 45 CEDEX 33076 F-, 33000, Bordeaux, France
- Department of Oral Medicine University Hospital of Bordeaux, CHU de Bordeaux, Place Amélie Rabat Léon, 33076, Bordeaux Cedex, France
| | - Philippe Barthélémy
- ARNA Laboratory, Inserm, U1212, CNRS 5320 (ChemBioPharm), University of Bordeaux, F-33000, Bordeaux, France.
| | - Adrien Naveau
- Biotis, Inserm, U1026 University of Bordeaux 146 rue Léo-Saignat, Case 45 CEDEX 33076 F-, 33000, Bordeaux, France
- Department of Oral Medicine University Hospital of Bordeaux, CHU de Bordeaux, Place Amélie Rabat Léon, 33076, Bordeaux Cedex, France
| | - Sylvie Crauste-Manciet
- ARNA Laboratory, Inserm, U1212, CNRS 5320 (ChemBioPharm), University of Bordeaux, F-33000, Bordeaux, France
- Pharmaceutical Technology Department, University Hospital of Bordeaux, CHU de Bordeaux, Avenue de Magellan, 33604, Pessac, France
| |
Collapse
|
3
|
Heloury J, Bouguéon G, Deljehier T, Jourand A, Berroneau A, Crauste-Manciet S. Automation of Aseptic Sterile Preparation: Risk Analysis and Productivity Comparison with Manual Process. Pharmaceutical Technology in Hospital Pharmacy 2019. [DOI: 10.1515/pthp-2019-0001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Two automation methods for aseptic preparation in hospital pharmacy, robot and peristaltic pump, were compared to manual process both for risk analysis using Failure Modes Effects and Criticality Analysis (FMECA) method and for productivity using time analysis grids built for each process.
The results obtained with the different workflow organizations showed that the worst-case conditions for productivity was production “on demand” of tailor-made preparations. in that case, the manual process was not significantly different from the robotic process (p-value=0.72). For the standardized preparations, the semi-automatic process preparing a batch from bulk solution from “to be reconstituted” drugs was significantly superior to the robotic process preparing repetitive series of doses (p-value<0.01). Productivity of the robot was dramatically increased when the robot performed standardized preparations either from ready to use solutions or mixed cycles due to the robot design. When different processes were FMECA analyzed for risk analysis the robotic process was found as the safer process in comparison to others with a total of Criticality Indexes of 1060, 719, 656 for manual, semi-automatic and robot, respectively. Except for the robotic, semi-automatic and manual processes needed additional IT control systems to limit the risk of failures.
Collapse
Affiliation(s)
- Jeanne Heloury
- Pharmaceutical Technology Department , Bordeaux University Hospital , Bordeaux , France
| | - Guillaume Bouguéon
- Pharmaceutical Technology Department , Bordeaux University Hospital , Bordeaux , France
- ARNA laboratory ChemBioPharm U1212 INSERM – UMR 5320 CNRS , Bordeaux University , Bordeaux , France
| | - Thomas Deljehier
- Pharmaceutical Technology Department , Bordeaux University Hospital , Bordeaux , France
| | - Audrey Jourand
- Quality department , Bordeaux University Hospital , Bordeaux , France
| | - Aude Berroneau
- Pharmaceutical Technology Department , Bordeaux University Hospital , Bordeaux , France
| | - Sylvie Crauste-Manciet
- Pharmaceutical Technology Department , Bordeaux University Hospital , Bordeaux , France
- ARNA laboratory ChemBioPharm U1212 INSERM – UMR 5320 CNRS , Bordeaux University , Bordeaux , France
| |
Collapse
|
4
|
Deljehier T, Bouguéon G, Heloury J, Moreno V, Berroneau A, Crauste-Manciet S. Simulation program of a cytotoxic compounding robot for monoclonal antibodies and anti-infectious sterile drug preparation. J Oncol Pharm Pract 2019; 25:1873-1890. [DOI: 10.1177/1078155218823911] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The aim of this study was to develop a specific simulation program for the validation of a cytotoxic compounding robot, KIRO® Oncology, for the preparation of sterile monoclonal antibodies and anti-infectious drugs. The impact of excipient formulations was clearly measured using simulation accuracy tests with worst case excipient (i.e. viscous, foaming) and allowed to correct the robotic settings prior to real production. Corrections brought accuracies within the acceptable range of ±5%. KIRO® Oncology robot has also the capacity of self-cleaning and a simulation combining media fill test, and environmental monitoring was able to validate the aseptic process including simulation of worst case conditions and highlighting the areas not accessible to self-cleaning to be corrected by additional manual cleaning measures. The risk of chemical contamination was simulated by using fluorescent dye of the process with high-risk excipient formulation and overpressure vials. Quality control reliability was simulated by using a model drug, and final concentration was determined by high-performance liquid chromatography-ultraviolet detection. Finally, productivity was simulated using different models of production showing the impact of the type of drug, the number of vials and the poor standardization of the process.
Collapse
Affiliation(s)
- Thomas Deljehier
- Pharmaceutical Technology Department, Bordeaux University Hospital, Bordeaux, France
| | - Guillaume Bouguéon
- Pharmaceutical Technology Department, Bordeaux University Hospital, Bordeaux, France
- ARNA Laboratory ChemBioPharm U1212 INSERM, UMR 5320 CNRS Bordeaux University, Bordeaux, France
| | - Jeanne Heloury
- Pharmaceutical Technology Department, Bordeaux University Hospital, Bordeaux, France
| | - Valérie Moreno
- Biomedical Department, Bordeaux University Hospital, Bordeaux, France
| | - Aude Berroneau
- Pharmaceutical Technology Department, Bordeaux University Hospital, Bordeaux, France
| | - Sylvie Crauste-Manciet
- Pharmaceutical Technology Department, Bordeaux University Hospital, Bordeaux, France
- ARNA Laboratory ChemBioPharm U1212 INSERM, UMR 5320 CNRS Bordeaux University, Bordeaux, France
| |
Collapse
|
5
|
Bouguéon G, Kauss T, Dessane B, Barthélémy P, Crauste-Manciet S. Micro- and nano-formulations for bioprinting and additive manufacturing. Drug Discov Today 2019; 24:163-178. [DOI: 10.1016/j.drudis.2018.10.013] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Revised: 09/05/2018] [Accepted: 10/25/2018] [Indexed: 02/06/2023]
|
6
|
Bouguéon G, Lagarce F, Martin L, Pailhoriès H, Bastiat G, Vrignaud S. Formulation and characterization of a 0.1% rapamycin cream for the treatment of Tuberous Sclerosis Complex-related angiofibromas. Int J Pharm 2016; 509:279-284. [DOI: 10.1016/j.ijpharm.2016.05.064] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2016] [Revised: 05/25/2016] [Accepted: 05/29/2016] [Indexed: 11/25/2022]
|
7
|
Bouguéon G, Vrignaud S, Martin L, Lagarce F. Traitement des angiofibromes de la sclérose tubéreuse de Bourneville par des préparations topiques à base de sirolimus : état des lieux de la préparation en France et revue de la littérature. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|